BR112022018504A2 - Usos de uma composição - Google Patents

Usos de uma composição

Info

Publication number
BR112022018504A2
BR112022018504A2 BR112022018504A BR112022018504A BR112022018504A2 BR 112022018504 A2 BR112022018504 A2 BR 112022018504A2 BR 112022018504 A BR112022018504 A BR 112022018504A BR 112022018504 A BR112022018504 A BR 112022018504A BR 112022018504 A2 BR112022018504 A2 BR 112022018504A2
Authority
BR
Brazil
Prior art keywords
viral infections
formula
composition
pharmaceutical compositions
ace2
Prior art date
Application number
BR112022018504A
Other languages
English (en)
Portuguese (pt)
Inventor
Lee Thompson Daryl
Original Assignee
Global Biolife Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Biolife Inc filed Critical Global Biolife Inc
Publication of BR112022018504A2 publication Critical patent/BR112022018504A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/366Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37Coumarins, e.g. psoralen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112022018504A 2020-03-16 2021-03-16 Usos de uma composição BR112022018504A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062990168P 2020-03-16 2020-03-16
PCT/US2021/022538 WO2021188520A1 (en) 2020-03-16 2021-03-16 Method and compositions for treating, preventing or limiting the occurrence of viral infection

Publications (1)

Publication Number Publication Date
BR112022018504A2 true BR112022018504A2 (pt) 2022-11-29

Family

ID=77768366

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022018504A BR112022018504A2 (pt) 2020-03-16 2021-03-16 Usos de uma composição

Country Status (9)

Country Link
US (1) US20230132782A1 (https=)
EP (1) EP4121040A4 (https=)
JP (1) JP2023518390A (https=)
KR (1) KR20230012469A (https=)
CN (1) CN115397410A (https=)
AU (1) AU2021236622A1 (https=)
BR (1) BR112022018504A2 (https=)
CA (1) CA3172162A1 (https=)
WO (1) WO2021188520A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230165831A1 (en) * 2021-11-19 2023-06-01 Impact Biolife Science, Inc. Method and composition for rendering cancer cells susceptible to treatment by targeted oncogenetic drivers
CN117462539A (zh) * 2023-12-26 2024-01-30 云南中医药大学 一种二氢黄酮醇型化合物的抗冠状病毒用途及制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1605335A (zh) * 2003-05-30 2005-04-13 任启生 含有二氢杨梅素和杨梅素的组合物用于抗病毒等药物
US8034838B2 (en) * 2008-05-29 2011-10-11 Daryl Lee Thompson Composition and method for the treatment of neurological disorders
CN101701245B (zh) * 2009-10-21 2013-06-19 中国科学院生物物理研究所 从中药中筛选sars冠状病毒主蛋白酶抑制剂的方法
US20140194500A1 (en) * 2013-01-08 2014-07-10 Kookmin University Industry Academic Cooperation Foundation Methods For Treating of SARS
US10383842B2 (en) * 2015-02-13 2019-08-20 Global Biolife Inc. Method and composition for preventing and treating viral infections
US12257231B2 (en) * 2015-02-13 2025-03-25 Global Biolife Inc. Method and composition for preventing and treating viral infections
US10123991B2 (en) * 2015-05-15 2018-11-13 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10966954B2 (en) * 2016-05-16 2021-04-06 Global Biolife Inc. Electrophilically enhanced phenolic compounds for treating inflammatory related diseases and disorders
US10987371B2 (en) * 2017-06-09 2021-04-27 Adaerata, Limited Partnership Methods of preventing or treating filovirus and flavivirus diseases
WO2019045677A1 (en) * 2017-08-28 2019-03-07 Global Biolife Inc. METHOD AND COMPOSITION FOR PREVENTING AND TREATING VIRAL INFECTIONS
CN113350330B (zh) * 2020-03-06 2023-04-14 中国科学院上海药物研究所 杨梅素类化合物在制备防治新冠肺炎药物中的应用
CN112546038A (zh) * 2020-11-19 2021-03-26 澳门科技大学 杨梅素在制备预防或治疗冠状病毒、流感病毒的药物中的应用
CN113244217A (zh) * 2021-06-25 2021-08-13 南开大学 二氢杨梅素在制备抑制新冠病毒或肺部纤维化的药物中的应用

Also Published As

Publication number Publication date
CA3172162A1 (en) 2021-09-23
WO2021188520A1 (en) 2021-09-23
US20230132782A1 (en) 2023-05-04
KR20230012469A (ko) 2023-01-26
CN115397410A (zh) 2022-11-25
JP2023518390A (ja) 2023-05-01
AU2021236622A1 (en) 2022-10-13
EP4121040A4 (en) 2024-07-17
EP4121040A1 (en) 2023-01-25

Similar Documents

Publication Publication Date Title
BR112022004424A2 (pt) Pró-fármacos antivirais e formulações dos mesmos
BR112021022778A2 (pt) Compostos e métodos para o tratamento de covid-19
BR112022026321A2 (pt) Análogos de 1'-ciano nucleosídeo e usos dos mesmos
BR112022010112A2 (pt) Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica
CO2019010295A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CL2022002481A1 (es) Compuestos antivirales y métodos para la administración de los mismos
BR112022000503A2 (pt) Compostos úteis para tratar infecções por vírus influenza
CO2019013042A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112023002951A2 (pt) Compostos de fosfolipídio e usos destes
CO2019010292A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
CO2019012035A2 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
BR112017012327A8 (pt) benzamidas substituídas por 1,3-tiazol-2-il.
BR112016003348A2 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade efetiva de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
ECSP18073293A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
BR112015022096A8 (pt) compostos moduladores de canal de sódio, composição que os compreende e uso dos mesmos
BR112015024552A2 (pt) compostos de fórmula (a), composição farmacêutica, métodos para a preparação do composto e métodos de tratamento ou prevenção de infecções
BR112019006802A2 (pt) compostos e métodos para diagnóstico e tratamento de infecções virais
BR112022018504A2 (pt) Usos de uma composição
BR112021025764A2 (pt) Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo
BR112022010798A2 (pt) Derivado de metileno-naftaleno-éter de fenilisoxazolila, seu uso e composição farmacêutica compreendendo o mesmo
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
BR112013032911A2 (pt) leucotoxina e/d como um novo agente anti-inflamatório e microbicida
BR112022019876A2 (pt) Composições virucidas, composição farmacêutica, método de desinfecção e/ou esterilização, dispositivo e uso das composições virucidas

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]